

COVID-19 Impact on Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C92F3A302128EN.html>

Date: September 2020

Pages: 92

Price: US\$ 3,900.00 (Single User License)

ID: C92F3A302128EN

Abstracts

This report focuses on the global Devic's Syndrome (Neuromyelitis Optica) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Devic's Syndrome (Neuromyelitis Optica) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Alexion Pharmaceuticals, Inc.

Teva Pharmaceuticals

Fresenius Kabi AG

Pharmacia & Upjohn (a subsidiary of Pfizer)

Lupin Ltd.

Sagent Pharmaceuticals, Inc.

Zydus Pharmaceuticals, Inc.

Sandoz Inc. (Novartis)

Alkem Laboratories Ltd.

Mylan Pharmaceuticals, Inc.

Hoffmann-La Roche/ Chugai Pharmaceutical

MedImmune LLC

RemeGen, Ltd.

Market segment by Type, the product can be split into

Eculizumab

Methylprednisolone

Azathioprine

Mycophenolate Mofetil

Rituximab

Market segment by Application, split into

Hospitals

Clinic

Others

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Devic's Syndrome (Neuromyelitis Optica) Treatment status, future forecast, growth opportunity, key market and key players.

To present the Devic's Syndrome (Neuromyelitis Optica) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Devic's Syndrome (Neuromyelitis Optica) Treatment are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue

1.4 Market Analysis by Type

1.4.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Eculizumab

1.4.3 Methylprednisolone

1.4.4 Azathioprine

1.4.5 Mycophenolate Mofetil

1.4.6 Rituximab

1.5 Market by Application

1.5.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2026

1.5.2 Hospitals

1.5.3 Clinic

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19): Devic's Syndrome (Neuromyelitis Optica) Treatment Industry Impact

1.6.1 How the Covid-19 is Affecting the Devic's Syndrome (Neuromyelitis Optica) Treatment Industry

1.6.1.1 Devic's Syndrome (Neuromyelitis Optica) Treatment Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Devic's Syndrome (Neuromyelitis Optica) Treatment Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Devic's Syndrome (Neuromyelitis Optica) Treatment Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2015-2026)

2.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions

2.2.1 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2015-2020)

2.2.3 Devic's Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Growth Strategy

2.3.6 Primary Interviews with Key Devic's Syndrome (Neuromyelitis Optica) Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Devic's Syndrome (Neuromyelitis Optica) Treatment Players by Market Size

3.1.1 Global Top Devic's Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2015-2020)

3.1.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2015-2020)

3.1.3 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio

3.2.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in 2019

3.3 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served

3.4 Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Product Solution

and Service

3.5 Date of Enter into Devic's Syndrome (Neuromyelitis Optica) Treatment Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2015-2020)

4.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2021-2026)

5 DEVIC'S SYNDROME (NEUROMYELITIS OPTICA) TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

5.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

6.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in North America (2019-2020)

6.3 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

6.4 North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

7.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in Europe (2019-2020)

7.3 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

7.4 Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by

Application (2015-2020)

8 CHINA

8.1 China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

8.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in China (2019-2020)

8.3 China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

8.4 China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

9.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in Japan (2019-2020)

9.3 Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

9.4 Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

10.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

10.4 Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

11.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in India (2019-2020)

11.3 India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

11.4 India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)

12.2 Devic's Syndrome (Neuromyelitis Optica) Treatment Key Players in Central & South America (2019-2020)

12.3 Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)

12.4 Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Alexion Pharmaceuticals, Inc.

13.1.1 Alexion Pharmaceuticals, Inc. Company Details

13.1.2 Alexion Pharmaceuticals, Inc. Business Overview and Its Total Revenue

13.1.3 Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction

13.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020))

13.1.5 Alexion Pharmaceuticals, Inc. Recent Development

13.2 Teva Pharmaceuticals

13.2.1 Teva Pharmaceuticals Company Details

13.2.2 Teva Pharmaceuticals Business Overview and Its Total Revenue

13.2.3 Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction

13.2.4 Teva Pharmaceuticals Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

13.2.5 Teva Pharmaceuticals Recent Development

13.3 Fresenius Kabi AG

13.3.1 Fresenius Kabi AG Company Details

13.3.2 Fresenius Kabi AG Business Overview and Its Total Revenue

- 13.3.3 Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
- 13.3.4 Fresenius Kabi AG Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
- 13.3.5 Fresenius Kabi AG Recent Development
- 13.4 Pharmacia & Upjohn (a subsidiary of Pfizer)
 - 13.4.1 Pharmacia & Upjohn (a subsidiary of Pfizer) Company Details
 - 13.4.2 Pharmacia & Upjohn (a subsidiary of Pfizer) Business Overview and Its Total Revenue
 - 13.4.3 Pharmacia & Upjohn (a subsidiary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 13.4.4 Pharmacia & Upjohn (a subsidiary of Pfizer) Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 13.4.5 Pharmacia & Upjohn (a subsidiary of Pfizer) Recent Development
- 13.5 Lupin Ltd.
 - 13.5.1 Lupin Ltd. Company Details
 - 13.5.2 Lupin Ltd. Business Overview and Its Total Revenue
 - 13.5.3 Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 13.5.4 Lupin Ltd. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 13.5.5 Lupin Ltd. Recent Development
- 13.6 Sagent Pharmaceuticals, Inc.
 - 13.6.1 Sagent Pharmaceuticals, Inc. Company Details
 - 13.6.2 Sagent Pharmaceuticals, Inc. Business Overview and Its Total Revenue
 - 13.6.3 Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 13.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 13.6.5 Sagent Pharmaceuticals, Inc. Recent Development
- 13.7 Zydus Pharmaceuticals, Inc.
 - 13.7.1 Zydus Pharmaceuticals, Inc. Company Details
 - 13.7.2 Zydus Pharmaceuticals, Inc. Business Overview and Its Total Revenue
 - 13.7.3 Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 13.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 13.7.5 Zydus Pharmaceuticals, Inc. Recent Development
- 13.8 Sandoz Inc. (Novartis)
 - 13.8.1 Sandoz Inc. (Novartis) Company Details

- 13.8.2 Sandoz Inc. (Novartis) Business Overview and Its Total Revenue
- 13.8.3 Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
- 13.8.4 Sandoz Inc. (Novartis) Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
- 13.8.5 Sandoz Inc. (Novartis) Recent Development
- 13.9 Alkem Laboratories Ltd.
 - 13.9.1 Alkem Laboratories Ltd. Company Details
 - 13.9.2 Alkem Laboratories Ltd. Business Overview and Its Total Revenue
 - 13.9.3 Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 13.9.4 Alkem Laboratories Ltd. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 13.9.5 Alkem Laboratories Ltd. Recent Development
- 13.10 Mylan Pharmaceuticals, Inc.
 - 13.10.1 Mylan Pharmaceuticals, Inc. Company Details
 - 13.10.2 Mylan Pharmaceuticals, Inc. Business Overview and Its Total Revenue
 - 13.10.3 Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 13.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 13.10.5 Mylan Pharmaceuticals, Inc. Recent Development
- 13.11 Hoffmann-La Roche/ Chugai Pharmaceutical
 - 10.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
 - 10.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview and Its Total Revenue
 - 10.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 10.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 10.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
- 13.12 MedImmune LLC
 - 10.12.1 MedImmune LLC Company Details
 - 10.12.2 MedImmune LLC Business Overview and Its Total Revenue
 - 10.12.3 MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Introduction
 - 10.12.4 MedImmune LLC Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
 - 10.12.5 MedImmune LLC Recent Development

13.13 RemeGen, Ltd.

10.13.1 RemeGen, Ltd. Company Details

10.13.2 RemeGen, Ltd. Business Overview and Its Total Revenue

10.13.3 RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment

Introduction

10.13.4 RemeGen, Ltd. Revenue in Devic's Syndrome (Neuromyelitis Optica)

Treatment Business (2015-2020)

10.13.5 RemeGen, Ltd. Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Devic's Syndrome (Neuromyelitis Optica) Treatment Key Market Segments

Table 2. Key Players Covered: Ranking by Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue

Table 3. Ranking of Global Top Devic's Syndrome (Neuromyelitis Optica) Treatment Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Eculizumab

Table 6. Key Players of Methylprednisolone

Table 7. Key Players of Azathioprine

Table 8. Key Players of Mycophenolate Mofetil

Table 9. Key Players of Rituximab

Table 10. COVID-19 Impact Global Market: (Four Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast Scenarios)

Table 11. Opportunities and Trends for Devic's Syndrome (Neuromyelitis Optica) Treatment Players in the COVID-19 Landscape

Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 13. Key Regions/Countries Measures against Covid-19 Impact

Table 14. Proposal for Devic's Syndrome (Neuromyelitis Optica) Treatment Players to Combat Covid-19 Impact

Table 15. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 16. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (US\$ Million): 2020 VS 2026

Table 17. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (2015-2020) (US\$ Million)

Table 18. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2015-2020)

Table 19. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 20. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2021-2026)

Table 21. Market Top Trends

Table 22. Key Drivers: Impact Analysis

Table 23. Key Challenges

Table 24. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Growth Strategy

Table 25. Main Points Interviewed from Key Devic's Syndrome (Neuromyelitis Optica) Treatment Players

Table 26. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2015-2020) (Million US\$)

Table 27. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Players (2015-2020)

Table 28. Global Top Devic's Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment as of 2019)

Table 29. Global Devic's Syndrome (Neuromyelitis Optica) Treatment by Players Market Concentration Ratio (CR5 and HHI)

Table 30. Key Players Headquarters and Area Served

Table 31. Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service

Table 32. Date of Enter into Devic's Syndrome (Neuromyelitis Optica) Treatment Market

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 35. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Type (2015-2020)

Table 36. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2021-2026)

Table 37. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Application (2015-2020)

Table 38. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 39. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Application (2021-2026)

Table 40. North America Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 41. North America Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 42. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 43. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 44. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market

Size by Application (2015-2020) (Million US\$)

Table 45. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 46. Europe Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 47. Europe Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 48. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 49. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 50. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 51. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 52. China Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 53. China Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 54. China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 55. China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 56. China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 57. China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 58. Japan Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 59. Japan Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 60. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 61. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 62. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 63. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 65. Southeast Asia Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 66. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 67. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 68. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 69. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 70. India Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 71. India Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 72. India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 73. India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 74. India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 75. India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 76. Central & South America Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US\$)

Table 77. Central & South America Key Players Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)

Table 78. Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US\$)

Table 79. Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)

Table 80. Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US\$)

Table 81. Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)

Table 82. Alexion Pharmaceuticals, Inc. Company Details

Table 83. Alexion Pharmaceuticals, Inc. Business Overview

Table 84. Alexion Pharmaceuticals, Inc. Product

Table 85. Alexion Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 86. Alexion Pharmaceuticals, Inc. Recent Development

Table 87. Teva Pharmaceuticals Company Details

Table 88. Teva Pharmaceuticals Business Overview

Table 89. Teva Pharmaceuticals Product

Table 90. Teva Pharmaceuticals Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 91. Teva Pharmaceuticals Recent Development

Table 92. Fresenius Kabi AG Company Details

Table 93. Fresenius Kabi AG Business Overview

Table 94. Fresenius Kabi AG Product

Table 95. Fresenius Kabi AG Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 96. Fresenius Kabi AG Recent Development

Table 97. Pharmacia & Upjohn (a subsidiary of Pfizer) Company Details

Table 98. Pharmacia & Upjohn (a subsidiary of Pfizer) Business Overview

Table 99. Pharmacia & Upjohn (a subsidiary of Pfizer) Product

Table 100. Pharmacia & Upjohn (a subsidiary of Pfizer) Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 101. Pharmacia & Upjohn (a subsidiary of Pfizer) Recent Development

Table 102. Lupin Ltd. Company Details

Table 103. Lupin Ltd. Business Overview

Table 104. Lupin Ltd. Product

Table 105. Lupin Ltd. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 106. Lupin Ltd. Recent Development

Table 107. Sagent Pharmaceuticals, Inc. Company Details

Table 108. Sagent Pharmaceuticals, Inc. Business Overview

Table 109. Sagent Pharmaceuticals, Inc. Product

Table 110. Sagent Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 111. Sagent Pharmaceuticals, Inc. Recent Development

Table 112. Zydus Pharmaceuticals, Inc. Company Details

Table 113. Zydus Pharmaceuticals, Inc. Business Overview

Table 114. Zydus Pharmaceuticals, Inc. Product

Table 115. Zydus Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 116. Zydus Pharmaceuticals, Inc. Recent Development

Table 117. Sandoz Inc. (Novartis) Business Overview

Table 118. Sandoz Inc. (Novartis) Product

Table 119. Sandoz Inc. (Novartis) Company Details

Table 120. Sandoz Inc. (Novartis) Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 121. Sandoz Inc. (Novartis) Recent Development

Table 122. Alkem Laboratories Ltd. Company Details

Table 123. Alkem Laboratories Ltd. Business Overview

Table 124. Alkem Laboratories Ltd. Product

Table 125. Alkem Laboratories Ltd. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 126. Alkem Laboratories Ltd. Recent Development

Table 127. Mylan Pharmaceuticals, Inc. Company Details

Table 128. Mylan Pharmaceuticals, Inc. Business Overview

Table 129. Mylan Pharmaceuticals, Inc. Product

Table 130. Mylan Pharmaceuticals, Inc. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 131. Mylan Pharmaceuticals, Inc. Recent Development

Table 132. Hoffmann-La Roche/ Chugai Pharmaceutical Company Details

Table 133. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview

Table 134. Hoffmann-La Roche/ Chugai Pharmaceutical Product

Table 135. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 136. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development

Table 137. MedImmune LLC Company Details

Table 138. MedImmune LLC Business Overview

Table 139. MedImmune LLC Product

Table 140. MedImmune LLC Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 141. MedImmune LLC Recent Development

Table 142. RemeGen, Ltd. Company Details

Table 143. RemeGen, Ltd. Business Overview

Table 144. RemeGen, Ltd. Product

Table 145. RemeGen, Ltd. Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US\$)

Table 146. RemeGen, Ltd. Recent Development

Table 147. Research Programs/Design for This Report

Table 148. Key Data Information from Secondary Sources

Table 149. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2020 VS 2026
- Figure 2. Eculizumab Features
- Figure 3. Methylprednisolone Features
- Figure 4. Azathioprine Features
- Figure 5. Mycophenolate Mofetil Features
- Figure 6. Rituximab Features
- Figure 7. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2026
- Figure 8. Hospitals Case Studies
- Figure 9. Clinic Case Studies
- Figure 10. Others Case Studies
- Figure 11. Devic's Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
- Figure 12. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 13. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions: 2020 VS 2026
- Figure 14. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2021-2026)
- Figure 15. Porter's Five Forces Analysis
- Figure 16. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2019
- Figure 17. Global Top Devic's Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devic's Syndrome (Neuromyelitis Optica) Treatment as of 2019)
- Figure 18. The Top 10 and 5 Players Market Share by Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in 2019
- Figure 19. North America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 20. Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 21. China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 22. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY

Growth (2015-2020) (Million US\$)

Figure 23. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. Central & South America Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Alexion Pharmaceuticals, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 28. Teva Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Teva Pharmaceuticals Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 30. Fresenius Kabi AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Fresenius Kabi AG Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 32. Pharmacia & Upjohn (a subsidiary of Pfizer) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Pharmacia & Upjohn (a subsidiary of Pfizer) Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 34. Lupin Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Lupin Ltd. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 36. Sagent Pharmaceuticals, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 38. Zydus Pharmaceuticals, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 40. Sandoz Inc. (Novartis) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 42. Alkem Laboratories Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Alkem Laboratories Ltd. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 44. Mylan Pharmaceuticals, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 46. Hoffmann-La Roche/ Chugai Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 48. MedImmune LLC Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. MedImmune LLC Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 50. RemeGen, Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. RemeGen, Ltd. Revenue Growth Rate in Devic's Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

Figure 54. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C92F3A302128EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C92F3A302128EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

